Susan Haigney

Automation of pharmaceutical packaging saves costs and time, say contract packagers.

The complex nature of biologics creates challenges for GMPs in sterile manufacturing, and the EU’s Annex 1 is making an impact.

CDMOs offer expertise and customization options for sponsors of orphan drugs.

Outsourcing partners are ready to fill the market need for greater cell therapies capacities.

Establishing a quality culture from the top of an organization down to each and every employee ensures a safe and effective product, and saves costs.

The booming cell therapy market has created a need for capacity that outsourcing partners are ready to fill.

Performing corrective action and preventive action (CAPA) activities is often necessary to investigate a manufacturing deviation and prevent it from reoccurring. BioPharm International asked Joe O’Gorman, head of Global Operations at LZ Lifescience, a Cognizant Company, about the role technology plays in performing CAPAs.

Disruptions in the bio/pharmaceutical supply chain can have serious impacts on the quality and availability of life-saving medicines.

As regulators balance pandemic tasks and rethink procedures, quality at manufacturing facilities is still a priority.

COVID-19 created challenges for quality control departments. How have the lessons learned from the pandemic influenced the way companies use technology to perform quality-control procedures?